Thiazolidinediones on PPARγ: The roles in bone remodeling

PPAR Research

Volumn , Issue , 2011, Pages

  Wei, Wei ^a   Wan, Yihong ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ACTIVIN; CATHEPSIN K; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FATTY ACID BINDING PROTEIN; FOLLISTATIN; FOLLITROPIN; GLUCOSE TRANSPORTER 4; I KAPPA B; INHIBIN; NETOGLITAZONE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; OXYTOCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROGESTERONE; PROLACTIN; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE;

ADIPOGENESIS; APOPTOSIS; BONE REMODELING; CELL DIFFERENTIATION; CELL SURVIVAL; ENZYME ACTIVITY; ESTROGEN SYNTHESIS; FRACTURE; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; SIDE EFFECT;

EID: 84855289573     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2011/867180     Document Type: Review

References (100)

1. Johnell O., Kanis J. A., An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporosis International 2006 17 12 1726 1733 (Pubitemid 44607392)
2. Melton L. J. III, Atkinson E. J., O'Connor M. K., O'Fallon W. M., Riggs B. L., Bone density and fracture risk in men Journal of Bone and Mineral Research 1998 13 12 1915 1923 (Pubitemid 28535849)
3. Melton L. J. III, Chrischilles E. A., Cooper C., Lane A. W., Riggs B. L., Perspective: how many women have osteoporosis? Journal of Bone and Mineral Research 1992 7 9 1005 1010
4. Kanis J. A., Johnell O., Oden A., Sernbo I., Redlund-Johnell I., Dawson A., de Laet C., Jonsson B., Long-term risk of osteoporotic fracture in Malmo Osteoporosis International 2000 11 8 669 674
5. Gullberg B., Johnell O., Kanis J. A., World-wide projections for hip fracture Osteoporosis International 1997 7 5 407 413 (Pubitemid 27443065)
6. Kanis J. A., Delmas P., Burckhardt P., Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease Osteoporosis International 1997 7 4 390 406
7. Nguyen T. V., Center J. R., Eisman J. A., Osteoporosis: underrated, underdiagnosed and undertreated Medical Journal of Australia 2004 180 supplement 5 S18 S22 (Pubitemid 38313000)
8. Boyle W. J., Simonet W. S., Lacey D. L., Osteoclast differentiation and activation Nature 2003 423 6937 337 342 (Pubitemid 40852708)
9. Edwards J. R., Mundy G. R., Advances in osteoclast biology: old findings and new insights from mouse models Nature Reviews Rheumatology 2011 7 4 235 243
10. Novack D. V., Teitelbaum S. L., The osteoclast: friend or foe? Annual Review of Pathology 2008 3 457 484 (Pubitemid 351488289)
11. Teitelbaum S. L., Ross F. P., Genetic regulation of osteoclast development and function Nature Reviews Genetics 2003 4 8 638 649 (Pubitemid 36917505)
12. Wan Y., PPAR in bone homeostasis Trends in Endocrinology and Metabolism 2010 21 12 722 728
13. Karsenty G., Transcriptional control of skeletogenesis Annual Review of Genomics and Human Genetics 2008 9 183 196
14. Robling A. G., Castillo A. B., Turner C. H., Biomechanical and molecular regulation of bone remodeling Annual Review of Biomedical Engineering 2006 8 455 498 (Pubitemid 44314825)
15. Karsenty G., Kronenberg H. M., Settembre C., Genetic control of bone formation Annual Review of Cell and Developmental Biology 2009 25 629 648
16. Jacobs C. R., Temiyasathit S., Castillo A. B., Osteocyte mechanobiology and pericellular mechanics Annual Review of Biomedical Engineering 2010 12 369 400
17. Bonewald L. F., The amazing osteocyte Journal of Bone and Mineral Research 2011 26 2 229 238
18. Nolan J. J., Ludvik B., Beerdsen P., Joyce M., Olefsky J., Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone New England Journal of Medicine 1994 331 18 1188 1193 (Pubitemid 24331336)
19. Suter S. L., Nolan J. J., Wallace P., Gumbiner B., Olefsky J. M., Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects Diabetes Care 1992 15 2 193 203
20. Kahn S. E., Haffner S. M., Heise M. A., Herman W. H., Holman R. R., Jones N. P., Kravitz B. G., Lachin J. M., O'Neill M. C., Zinman B., Viberti G., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy New England Journal of Medicine 2006 355 23 2427 2443 (Pubitemid 44903747)
21. Takeda, Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus. (Letter to Health Care Providers). http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/UCM153896.pdf, March 2007
22. Zinman B., Haffner S. M., Herman W. H., Holman R. R., Lachin J. M., Kravitz B. G., Paul G., Jones N. P., Aftring R. P., Viberti G., Kahn S. E., Kahn S., Haffner S., Herman W., Holman R., Aftring P., Jones N., Lachin J., Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes Journal of Clinical Endocrinology and Metabolism 2010 95 1 134 142
23. Lazarenko O. P., Rzonca S. O., Hogue W. R., Swain F. L., Suva L. J., Lecka-Czernik B., Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone Endocrinology 2007 148 6 2669 2680 (Pubitemid 46984815)
24. Grey A., Thiazolidinedione-induced skeletal fragilitymechanisms and implications Diabetes, Obesity and Metabolism 2009 11 4 275 284
25. Strotmeyer E. S., Cauley J. A., Diabetes mellitus, bone mineral density, and fracture risk Current Opinion in Endocrinology, Diabetes and Obesity 2007 14 6 429 435 (Pubitemid 350059352)
26. McCabe L. R., Understanding the pathology and mechanisms of type I diabetic bone loss Journal of Cellular Biochemistry 2007 102 6 1343 1357 (Pubitemid 350223938)
27. de Paula F. J., Horowitz M. C., Rosen C. J., Novel insights into the relationship between diabetes and osteoporosis Diabetes/Metabolism Research and Reviews 2010 26 8 622 630
28. Hamada Y., Fujii H., Fukagawa M., Role of oxidative stress in diabetic bone disorder Bone 2009 45 supplement 1 S35 S38
29. Tontonoz P., Spiegelman B. M., Fat and beyond: the diverse biology of PPARγ Annual Review of Biochemistry 2008 77 289 312
30. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U. I., Kubota N., Terauchi Y., Harada Y., Azuma Y., Nakamura K., Kadowaki T., Kawaguchi H., PPAR insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors Journal of Clinical Investigation 2004 113 6 846 855 (Pubitemid 38544143)
31. Ali A. A., Weinstein R. S., Stewart S. A., Parfitt A. M., Manolagas S. C., Jilka R. L., Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 2005 146 3 1226 1235 (Pubitemid 40289310)
32. Lecka-Czernik B., Gubrij I., Moerman E. J., Kajkenova O., Lipschitz D. A., Manolagas S. C., Jilka R. L., Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR 2 Journal of Cellular Biochemistry 1999 74 3 357 371 (Pubitemid 29344887)
33. Rzonca S. O., Suva L. J., Gaddy D., Montague D. C., Lecka-Czernik B., Bone is a target for the antidiabetic compound rosiglitazone Endocrinology 2004 145 1 401 406 (Pubitemid 38094536)
34. Mabilleau G., Mieczkowska A., Edmonds M. E., Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression Diabetic Medicine 2010 27 8 925 932
35. Sorocéanu M. A., Miao D., Bai X. Y., Su H., Goltzman D., Karaplis A. C., Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis Journal of Endocrinology 2004 183 1 203 216 (Pubitemid 40124657)
36. Wan Y., Chong L. W., Evans R. M., PPAR- regulates osteoclastogenesis in mice Nature Medicine 2007 13 12 1496 1503
37. Wei W., Wang X., Yang M., Smith L. C., Dechow P. C., Wan Y., PGC1 mediates PPAR activation of osteoclastogenesis and rosiglitazone-induced bone loss Cell Metabolism 2010 11 6 503 516
38. Wei W., Zeve D., Suh J. M., Biphasic and dosage-dependent regulation of osteoclastogenesis by -catenin. Molecular and Cellular Biology. In press
39. Pfeilschifter J., Chenu C., Bird A., Mundy G. R., Roodman G. D., Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro Journal of Bone and Mineral Research 1989 4 1 113 118 (Pubitemid 19079131)
40. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Morinaga T., Higashio K., Martin T. J., Suda T., Tumor necrosis factor stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction Journal of Experimental Medicine 2000 191 2 275 286
41. Edwards J. R., Sun S. G., Locklin R., Shipman C. M., Adamopoulos I. E., Athanasou N. A., Sabokbar A., LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis Arthritis and Rheumatism 2006 54 5 1451 1462
42. Ishimi Y., Miyaura C., Jin C. H., Akatsu T., Abe E., Nakamura Y., Yamaguchi A., Yoshiki S., Matsuda T., Hirano T., Kishimoto T., Suda T., IL-6 is produced by osteoblasts and induces bone resorption Journal of Immunology 1990 145 10 3297 3303
43. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., Koishihara Y., Ohsugi Y., Kumaki K., Taga T., Kishimoto T., Suda T., Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6 Proceedings of the National Academy of Sciences of the United States of America 1993 90 24 11924 11928 (Pubitemid 24008752)
44. Fujikawa Y., Sabokbar A., Neale S. D., Itonaga I., Torisu T., Athanasou N. A., The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells Bone 2001 28 3 261 267 (Pubitemid 32194418)
45. Itonaga I., Sabokbar A., Sun S. G., Kudo O., Danks L., Ferguson D., Fujikawa Y., Athanasou N. A., Transforming growth factor- induces osteoclast formation in the absence of RANKL Bone 2004 34 1 57 64 (Pubitemid 38142434)
46. Hemingway F., Taylor R., Knowles H. J., Athanasou N. A., RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II Bone 2011 48 4 938 944
47. Home P. D., Pocock S. J., Beck-Nielsen H., Curtis P. S., Gomis R., Hanefeld M., Jones N. P., Komajda M., McMurray J. J., Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial The Lancet 2009 373 9681 2125 2135
48. Kahn S. E., Zinman B., Lachin J. M., Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT) Diabetes Care 2008 31 5 845 851
49. Li M., Pan L. C., Simmons H. A., Li Y., Healy D. R., Robinson B. S., Ke H. Z., Brown T. A., Surface-specific effects of a PPAR agonist, darglitazone, on bone in mice Bone 2006 39 4 796 806 (Pubitemid 44311719)
50. Sottile V., Seuwen K., Kneissel M., Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPAR agonist BRL49653 (rosiglitazone) Calcified Tissue International 2004 75 4 329 337 (Pubitemid 40064235)
51. Rachner T. D., Khosla S., Hofbauer L. C., Osteoporosis: now and the future The Lancet 2011 377 9773 1276 1287
52. Takagi K., Kudo A., Bone marrow stromal cell lines having high potential for osteoclast-supporting activity express PPAR 1 and show high potential for differentiation into adipocytes Journal of Bone and Mineral Metabolism 2008 26 1 13 23 (Pubitemid 350308000)
53. Cho S. W., Yang J. Y., Her S. J., Osteoblast-targeted overexpression of PPAR inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice Journal of Bone and Mineral Research 2011 26 8 1939 1952
54. Park J. S., Cho M. H., Nam J. S., Yoo J. S., Ahn C. W., Cha B. S., Kim K. R., Lee H. C., Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus European Journal of Endocrinology 2011 164 1 69 74
55. Sultan A., Avignon A., Galtier F., Piot C., Mariano-Goulart D., Dupuy A. M., Cristol J. P., Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients Diabetes Care 2008 31 3 593 595
56. Krause U., Harris S., Green A., Ylostalo J., Zeitouni S., Lee N., Gregory C. A., Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy Proceedings of the National Academy of Sciences of the United States of America 2010 107 9 4147 4152
57. Krum S. A., Direct transcriptional targets of sex steroid hormones in bone Journal of Cellular Biochemistry 2011 112 2 401 408
58. Wei W., Zeve D., Wang X., Osteoclast progenitors reside in PPAR -expressing bone marrow cell population. Molecular and Cellular Biology. In press
59. Krum S. A., Miranda-Carboni G. A., Hauschka P. V., Carroll J. S., Lane T. F., Freedman L. P., Brown M., Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival EMBO Journal 2008 27 3 535 545 (Pubitemid 351225684)
60. Nakamura T., Imai Y., Matsumoto T., Sato S., Takeuchi K., Igarashi K., Harada Y., Azuma Y., Krust A., Yamamoto Y., Nishina H., Takeda S., Takayanagi H., Metzger D., Kanno J., Takaoka K., Martin T. J., Chambon P., Kato S., Estrogen prevents bone loss via estrogen receptor and induction of fas ligand in osteoclasts Cell 2007 130 5 811 823 (Pubitemid 47332572)
61. Bilik D., McEwen L. N., Brown M. B., Pomeroy N. E., Kim C., Asao K., Crosson J. C., Duru O. K., Ferrara A., Hsiao V. C., Karter A. J., Lee P. G., Marrero D. G., Selby J. V., Subramanian U., Herman W. H., Thiazolidinediones and fractures: evidence from translating research into action for diabetes Journal of Clinical Endocrinology and Metabolism 2010 95 10 4560 4565
62. Grey A., Bolland M., Gamble G., Wattie D., Horne A., Davidson J., Reid I. R., The peroxisome proliferator-activated receptor- agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial Journal of Clinical Endocrinology and Metabolism 2007 92 4 1305 1310 (Pubitemid 46556402)
63. Benvenuti S., Cellai I., Luciani P., Androgens and estrogens prevent rosiglitazone-induced adipogenesis in human mesenchymal stem cells. Journal of Endocrinology Investment. In press
64. Seto-Young D., Avtanski D., Parikh G., Suwandhi P., Strizhevsky M., Araki T., Rosenwaks Z., Poretsky L., Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase Hormone and Metabolic Research 2011 43 4 250 256
65. Lecomte J., Flament S., Salamone S., Disruption of ER signalling pathway by PPAR agonists: evidences of PPAR -independent events in two hormone-dependent breast cancer cell lines Breast Cancer Research and Treatment 2008 112 3 437 451
66. Bonofiglio D., Gabriele S., Aquila S., Qi H., Belmonte M., Catalano S., And S., Peroxisome proliferator-activated receptor activates fas ligand gene promoter inducing apoptosis in human breast cancer cells Breast Cancer Research and Treatment 2009 113 3 423 434
67. Vanacker J. M., Bonnelye E., Chopin-Delannoy S., Transcriptional activities of the orphan nuclear receptor ERR (estrogen receptor-related receptor- ) Molecular Endocrinology 1999 13 5 764 773 (Pubitemid 30645329)
68. Vanacker J. M., Pettersson K., Gustafsson J. A., Laudet V., Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER), but not by ER EMBO Journal 1999 18 15 4270 4279 (Pubitemid 29364129)
69. Stein R. A., McDonnell D. P., Estrogen-related receptor as a therapeutic target in cancer Endocrine-Related Cancer 2006 13 supplement 1 S25 S32 (Pubitemid 46219246)
70. Gallet M., Vanacker J. M., ERR receptors as potential targets in osteoporosis Trends in Endocrinology and Metabolism 2010 21 10 637 641
71. Ishii K. A., Fumoto T., Iwai K., Takeshita S., Ito M., Shimohata N., Aburatani H., Taketani S., Lelliott C. J., Vidal-Puig A., Ikeda K., Coordination of PGC-1 and iron uptake in mitochondrial biogenesis and osteoclast activation Nature Medicine 2009 15 3 259 266
72. Ryan K. K., Li B., Grayson B. E., A role for central nervous system PPAR- in the regulation of energy balance Nature Medicine 2011 17 5 623 626
73. Nicks K. M., Fowler T. W., Gaddy D., Reproductive hormones and bone Current Osteoporosis Reports 2010 8 2 60 67
74. Seifert-Klauss V., Prior J. C., Progesterone and bone: actions promoting bone health in women Journal of Osteoporosis 2010 2010
75. Schramek D., Leibbrandt A., Sigl V., Kenner L., Pospisilik J. A., Lee H. J., Hanada R., Joshi P. A., Aliprantis A., Glimcher L., Pasparakis M., Khokha R., Ormandy C. J., Widschwendter M., Schett G., Penninger J. M., Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer Nature 2010 468 7320 98 102
76. Wang P., Dharmaraj N., Brayman M. J., Carson D. D., Peroxisome proliferator-activated receptor activation inhibits progesterone-stimulated human MUC1 expression Molecular Endocrinology 2010 24 7 1368 1379
77. Ling N., Ying S. Y., Ueno N., Pituitary FSH is released by a heterodimer of the -subunits from the two forms of inhibin Nature 1986 321 6072 779 782 (Pubitemid 16077905)
78. Nicks K. M., Perrien D. S., Akel N. S., Suva L. J., Gaddy D., Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin Molecular and Cellular Endocrinology 2009 310 1-2 11 20
79. Hirai S., Yamanaka M., Kawachi H., Matsui T., Yano H., Activin A inhibits differentiation of 3T3-L1 preadipocyte Molecular and Cellular Endocrinology 2005 232 1-2 21 26 (Pubitemid 40292936)
80. Necela B. M., Su W., Thompson E. A., Peroxisome proliferator-activated receptor down-regulates follistatin in intestinal epithelial cells through SP1 Journal of Biological Chemistry 2008 283 44 29784 29794
81. Ebeling P. R., Atley L. M., Guthrie J. R., Burger H. G., Dennerstein L., Hopper J. L., Wark J. D., Bone turnover markers and bone density across the menopausal transition Journal of Clinical Endocrinology and Metabolism 1996 81 9 3366 3371 (Pubitemid 26296217)
82. Sowers M. R., Finkelstein J. S., Ettinger B., Bondarenko I., Neer R. M., Cauley J. A., Sherman S., Greendale G. A., The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN Osteoporosis International 2003 14 1 44 52 (Pubitemid 36267900)
83. Sowers M. R., Greendale G. A., Bondarenko I., Finkelstein J. S., Cauley J. A., Neer R. M., Ettinger B., Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN Osteoporosis International 2003 14 3 191 197 (Pubitemid 40826231)
84. Sun L., Peng Y., Sharrow A. C., Iqbal J., Zhang Z., Papachristou D. J., Zaidi S., Zhu L. L., Yaroslavskiy B. B., Zhou H., Zallone A., Sairam M. R., Kumar T. R., Bo W., Braun J., Cardoso-Landa L., Schaffler M. B., Moonga B. S., Blair H. C., Zaidi M., FSH directly regulates bone mass Cell 2006 125 2 247 260
85. Drake M. T., McCready L. K., Hoey K. A., Atkinson E. J., Khosla S., Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women Journal of Clinical Endocrinology and Metabolism 2010 95 11 5063 5068
86. Allan C. M., Kalak R., Dunstan C. R., McTavish K. J., Zhou H., Handelsman D. J., Seibel M. J., Follicle-stimulating hormone increases bone mass in female mice Proceedings of the National Academy of Sciences of the United States of America 2010 107 52 22629 22634
87. Bogazzi F., Russo D., Locci M. T., Chifenti B., Ultimieri F., Raggi F., Viacava P., Cecchetti D., Cosci C., Sardella C., Acerbi G., Gasperi M., Martino E., Peroxisome proliferator-activated receptor (PPAR) is highly expressed in normal human pituitary gland Journal of Endocrinological Investigation 2005 28 10 899 904 (Pubitemid 43162820)
88. Sharma S., Sharma P. M., Mistry D. S., Chang R. J., Olefsky J. M., Mellon P. L., Webster N. J.G., PPARG regulates gonadotropin-releasing hormone signaling in L T2 cells in vitro and pituitary gonadotroph function in vivo in mice Biology of Reproduction 2011 84 3 466 475
89. Heaney A. P., Fernando M., Melmed S., PPAR- receptor ligands: novel therapy for pituitary adenomas Journal of Clinical Investigation 2003 111 9 1381 1388 (Pubitemid 36554709)
90. Elabd C., Basillais A., Beaupied H., Breuil V., Wagner N., Scheideler M., Zaragosi L. E., Massiéra F., Lemichez E., Trajanoski Z., Carle G., Euller-Ziegler L., Ailhaud G., Benhamou C. L., Dani C., Amri E. Z., Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis Stem Cells 2008 26 9 2399 2407
91. Colucci S., Colaianni G., Mori G., Grano M., Zallone A., Human osteoclasts express oxytocin receptor Biochemical and Biophysical Research Communications 2002 297 3 442 445
92. Tamma R., Colaianni G., Zhu L. L., DiBenedetto A., Greco G., Montemurro G., Patano N., Strippoli M., Vergari R., Mancini L., Colucci S., Grano M., Faccio R., Liu X., Li J., Usmani S., Bachar M., Bab I., Nishimori K., Young L. J., Buettner C., Iqbal J., Sun L., Zaidi M., Zallone A., Oxytocin is an anabolic bone hormone Proceedings of the National Academy of Sciences of the United States of America 2009 106 17 7149 7154
93. Eckertova M., Ondrejcakova M., Krskova K., Zorad S., Jezova D., Subchronic treatment of rats with oxytocin results in improved adipocyte differentiation and increased gene expression of factors involved in adipogenesis British Journal of Pharmacology 2011 162 2 452 463
94. Seriwatanachai D., Thongchote K., Charoenphandhu N., Pandaranandaka J., Tudpor K., Teerapornpuntakit J., Suthiphongchai T., Krishnamra N., Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor B ligand/osteoprotegerin ratio Bone 2008 42 3 535 546
95. Nanbu-Wakao R., Fujitani Y., Masuho Y., Muramatu M. A., Wakao H., Prolactin enhances CCAAT enhancer-binding protein- (C/EBP ) and peroxisome proliferator-activated receptor (PPAR ) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells Molecular Endocrinology 2000 14 2 307 316 (Pubitemid 32295399)
96. Gruszka A., Kunert-Radek J., Pawlikowski M., Rosiglitazone, PPAR- receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro Neuroendocrinology Letters 2005 26 1 51 54 (Pubitemid 40394156)
97. Lecka-Czernik B., Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis Current Osteoporosis Reports 2010 8 4 178 184
98. Lazarenko O. P., Rzonca S. O., Suva L. J., Lecka-Czernik B., Netoglitazone is a PPAR- ligand with selective effects on bone and fat Bone 2006 38 1 74 84 (Pubitemid 43006077)
99. Choi J. H., Banks A. S., Estall J. L., Kajimura S., Bostrm P., Laznik D., Ruas J. L., Chalmers M. J., Kamenecka T. M., Blher M., Griffin P. R., Spiegelman B. M., Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR 3 by Cdk5 Nature 2010 466 7305 451 456
100. Derosa G., Maffioli P., Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes Diabetes Research and Clinical Practice 2011 91 3 265 270